CORONA REMEDIES LIMITED Share Price

CORONA REMEDIES LIMITED Share Price

NSE: CORONA
|
Pharmaceuticals
|
S Cap
₹ 2,200.80
+₹3.60 (0.16%)
1D
Last updated 10 Sep, 2026, 15:50 IST

CORONA REMEDIES LIMITED Share Price Today

As of 10 Sep 2026, CORONA REMEDIES LIMITED share price is ₹2,200.80. The stock opened at ₹2,208.20, compared to its previous close of ₹2,197.20. During today's trading session, CORONA REMEDIES LIMITED share price moved in the range of ₹2,060.50 to ₹2,225.00, with an average price of ₹2,142.75 for the day. Looking at its last 52-week, the stock has touched a low of ₹1,336.60 and a high of ₹2,270.10. On the performance front, CORONA REMEDIES LIMITED share price has increased by 40.18% over the last six months and is up 52.75% on a year-on-year basis.

₹2,060.50
0.16% up today
₹2,225.00
1D LOW
1D HIGH

CORONA REMEDIES LIMITED Returns Calculator

Circuit
L
H
₹1,757.80
₹2,636.60
52-week
L
H
₹1,336.60
₹2,270.10

About CORONA REMEDIES LIMITED

CORONA REMEDIES LIMITED Share Price
ISIN
INE02ZQ01018
Sector Market Cap
₹ 13,389.78 Cr

Corona Remedies Limited is an India-based pharmaceutical formulation company. The Company is engaged in developing, manufacturing and marketing products in women’s healthcare, cardio-diabetes, pain management, urology and other/multispecialty pharmaceuticals (comprising vitamins/minerals/nutrition (VMN), gastrointestinal and respiratory). Its diverse product portfolio comprises approximately 67 brands catering to a range of therapeutic areas. It has four dosage forms in pain management formulations, which it offers in the form of tablets, capsules, sprays and injections for treatments associated with musculoskeletal spasms and diabetes. It holds brands across the women’s healthcare lifecycle, from adolescence to infertility, pregnancy, post-pregnancy and pre- and post-menopause categories. Its brands include such as C-HOP; Trazer; COR; Cortel; Rosuless; Bisobis; Sitabite; Dapabite; Fur; Voglibite; Angiwell; Stimucor; Argihope, and others.

CORONA REMEDIES LIMITED Financial Highlights

  • Revenue: CORONA REMEDIES LIMITED reported revenue of ₹1,413.83 crore in FY26 vs ₹1,202.35 crore in FY25. It showed an increase of 17.59% on a yearly basis.
  • Operating Profit: CORONA REMEDIES LIMITED reported an operating profit of ₹240.42 crore in FY26 vs ₹198.53 crore in FY25. It showed an increase of 21.10% on a year-on-year basis.
  • Net Profit: CORONA REMEDIES LIMITED reported a net profit of ₹185.12 crore in FY26 vs ₹149.43 crore in FY25. It showed an increase of 23.88% on a yearly basis.

CORONA REMEDIES LIMITED Quarterly Result Highlights

  • CORONA REMEDIES LIMITED reported revenue of ₹425.58 crore in Jun 2026, compared with ₹357.20 crore in Mar 2026, representing an increase of 19.14% on a quarter-on-quarter (QoQ) basis.
  • CORONA REMEDIES LIMITED reported an operating profit of ₹80.36 crore in Jun 2026, compared with ₹54.74 crore in Mar 2026, representing an increase of 46.80% on a quarter-on-quarter (QoQ) basis.
  • CORONA REMEDIES LIMITED reported a profit of ₹60.11 crore in Jun 2026, compared with ₹45.33 crore in Mar 2026, reflecting an increase of 32.61% on a QoQ basis.
  • The earnings per share (EPS) of CORONA REMEDIES LIMITED stood at ₹30.27 during Jun 2026.

Data Source: BSE, Company announcements

Securities shown are illustrative, not recommendations. Past performance does not guarantee future results.

Know more
Promoters
69.00%
FII
3.63%
Other DII
0.40%
Retail and other
14.48%
Mutual funds
12.50%
Foreign Institutional Investor (FII)
FII shareholding by period
Apr 20250.00%
Dec 20251.84%
Mar 20262.25%
Jun 20263.63%
Mkt Cap Cr
13,389.80
P/E
67.28
P/B
17.93
ROE
24.79%
D/E
0.22
ROCE
27.13%
Div. Yield
0.46%
EPS(TTM)
30.22
Turnover
1.23
EV/EBITDA
41.70
Net Margin
13.17%
Op. Margin
20.31%
ROA
16.52%
Quick Ratio
0.62
Curr. Ratio
1.62
Based on fundamentals, this stock's
Step 5 of 5
Performance
Excellent
Corona Remedies outperforming all market indices
Step 1 of 5
Valuation
Overvalued
Corona Remedies appears overvalued compared to its peers
Step 5 of 5
Earnings
Excellent
Corona Remedies revenue, operating profit and net profit are growing
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROED/EROCEBook ValueDiv. YieldTurnoverEPS(TTM)
Sun Pharmaceutical Industries4,48,316.0037.005.3613.74%0.6117.33%93.240.86%0.4810.90
Divis Laboratories2,51,737.0086.0715.0215.32%0.0019.56%629.490.32%0.5598.19
Torrent Pharmaceuticals1,87,594.0087.0122.3125.49%1.6913.85%222.760.69%0.4958.70
Zydus Lifesciences1,12,618.0024.524.1518.59%0.3117.35%237.300.09%0.3335.38
Cipla1,10,515.0032.933.2111.27%0.0014.95%423.360.95%0.4543.52
Laurus Labs1,04,456.0095.8019.7116.77%0.4016.14%97.200.10%0.6713.72
Aurobindo Pharma97,238.9026.212.579.25%0.1911.76%394.820.24%0.3841.58
Lupin95,660.0017.234.2623.76%0.0424.88%659.000.86%0.57129.18
Dr. Reddy's Laboratories95,420.6029.972.5111.07%0.1812.54%377.950.70%0.4138.68
Mankind Pharma93,596.0045.275.7411.74%0.3413.13%396.980.04%0.4449.37

Auto-generated based on historical fundamentals; not a recommendation to buy/sell.

CORONA REMEDIES LIMITED Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹1,403.18₹1,196.42₹1,014.47₹884.05
Other Income₹10.65₹5.93₹6.46₹7.05
Total Revenue₹1,413.83₹1,202.35₹1,020.93₹891.10
Total Expenses₹1,154.58₹1,004.20₹902.46₹780.44
Profit Before Tax₹240.42₹198.53₹118.48₹110.89
Tax₹55.30₹49.10₹27.98₹25.96
Profit After Tax₹185.12₹149.43₹90.50₹84.93
EPS - Basic₹30.27₹24.43₹14.80₹14.57
EPS - Diluted₹30.27₹24.43₹14.80₹14.57

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹240.42₹198.53₹118.48₹110.89
Income before WC changes₹284.77₹250.84₹165.35₹133.44
Change in Assets-₹32.73-₹51.80-₹11.87-₹33.63
Change in Liabilities₹26.86₹34.73₹21.19₹28.72
Change in WC-₹5.87-₹17.07₹9.32-₹4.92
Cash flow from Operations₹229.48₹190.49₹156.76₹102.70
Cash flow from Investing-₹256.15-₹83.86-₹266.64-₹50.25
Cash flow from Financing₹25.28-₹106.57₹98.55-₹44.75
Total Cash Flow-₹1.39₹0.06-₹11.34₹7.71
Cash (Start of the year)₹3.22₹3.16₹14.49₹6.82
Cash (End of the year)₹1.83₹3.22₹3.16₹14.49

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹856.83₹590.99₹540.66₹303.54
Current Assets₹348.31₹338.87₹289.92₹291.49
Total Assets₹1,205.14₹929.86₹830.58₹595.02
Current Liabilities₹361.17₹239.59₹224.19₹137.37
Net Current Asset-₹12.86₹99.28₹65.72₹154.12
Non-Current Liabilities₹97.11₹83.93₹125.98₹49.13
Equity Capital₹746.86₹606.34₹480.41₹408.52
Total Equity & Liabilities₹1,205.14₹929.86₹830.58₹595.02

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹1,403.18₹1,196.42₹1,014.47₹884.05
Other Income₹10.65₹5.93₹6.46₹7.05
Total Revenue₹1,413.83₹1,202.35₹1,020.93₹891.10
Total Expenses₹1,154.58₹1,004.20₹902.46₹780.44
Profit Before Tax₹240.15₹198.15₹118.48₹110.66
Tax₹55.30₹49.10₹27.98₹25.96
Profit After Tax₹184.85₹149.05₹90.50₹84.70
EPS - Basic₹30.22₹24.37₹14.80₹14.53
EPS - Diluted₹30.22₹24.37₹14.80₹14.53

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹240.15₹198.15₹118.48₹110.66
Income before WC changes₹284.77₹250.84₹165.35₹133.44
Change in Assets-₹32.73-₹51.80-₹11.87-₹33.63
Change in Liabilities₹26.86₹34.73₹21.19₹28.72
Change in WC-₹5.87-₹17.07₹9.32-₹4.91
Cash flow from Operations₹229.48₹190.49₹156.76₹102.70
Cash flow from Investing-₹256.15-₹83.86-₹266.65-₹50.25
Cash flow from Financing₹25.28-₹106.57₹98.54-₹44.75
Total Cash Flow-₹1.39₹0.06-₹11.34₹7.71
Cash (Start of the year)₹3.22₹3.16₹14.49₹6.82
Cash (End of the year)₹1.83₹3.22₹3.16₹14.49

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹855.94₹590.37₹540.42₹303.31
Current Assets₹348.31₹338.87₹289.92₹291.49
Total Assets₹1,204.25₹929.24₹830.34₹594.80
Current Liabilities₹361.17₹239.59₹224.19₹137.37
Net Current Asset-₹12.86₹99.28₹65.73₹154.12
Non-Current Liabilities₹97.11₹83.93₹125.98₹49.13
Equity Capital₹745.97₹605.72₹480.18₹408.29
Total Equity & Liabilities₹1,204.25₹929.24₹830.34₹594.80
* All values are in INR Crore
Qty
Bid
0
0
0
0
0
0
0
0
0
0
Ask
Qty
2200.8
10
0
0
0
0
0
0
0
0
Bid Total: 0
Ask Total: 10
Buy orders: 0%
Sell orders: 100%
Bearish
2
Neutral
5
Bullish
1
Slightly Bearish
by SEBI experts
Expert Pick
EXPPICK
Stop-loss
Entry price
Target
Indicator
Value
Verdict
RSI (14)
62.52
Neutral
ATR (14)
58.28
Neutral
STOCH(9,6)
78.08
Neutral
STOCH RSI (14)
100
Bearish
ADX(9)
25.11
Bearish
UO(9)
54.11
Neutral
ROC(12)
2.24
Bullish
WillR(14)
-21.92
Neutral
Period
Simple value
Exponential vaue
5D
2117.94
2123.47
10D
2089.02
2107.97
20D
2107.61
2100.64
50D
2082.02
2049.51
100D
1915.74
1978.53
Volume trend — traded volume by day
10 Sep3L
9 Sep2L
8 Sep0L
7 Sep0L
4 Sep0L
3 Sep0L
Average1L

Technical indicators used here are for indicative purposes only. Kindly do not treat it as an investment or trading advice

Compare against other stocks
CORONA REMEDIES LIMITED Share Price
CORONA REMEDIES LIMITED
Pharmaceuticals
Add Stock
Add Another

CORONA REMEDIES LIMITED Share Price FAQs

CORONA REMEDIES LIMITED share price data is sourced from NSE/BSE and may be delayed. It is displayed for informational purposes only and does not constitute investment advice or a recommendation to buy or sell.

Trusted by 2 Crore+ Indians for their wealth-building needs. SEBI Registered Broker. SEBI Reg No. INZ000315837